Synageva BioPharma Corp and to-BBB to Collaborate on Brain Drug Delivery for Rare Diseases

LEXINGTON, Mass. & LEIDEN, Netherlands--(BUSINESS WIRE)-- Synageva BioPharma Corp. and to-BBB technologies BV, the Dutch drug brain delivery company, have entered into a research collaboration to evaluate the potential of transporting therapeutic proteins across the blood-brain barrier into the central nervous system (CNS). The blood-brain barrier, a protective filter for the CNS, can be an obstacle for protein therapeutics and prevent these treatments from reaching their site of action within the CNS. A number of rare diseases that could benefit from protein therapeutics have a CNS component and require the therapies to be transported across the blood-brain barrier. This research collaboration will be the basis for a development program for therapies for multiple such rare diseases, including Lysosomal Storage Diseases (LSDs).

“Synageva is pleased to have entered into this collaboration with to-BBB to evaluate their drug delivery technology,” said Anthony Quinn, Synageva’s Chief Medical Officer and Head of R&D. “This collaboration, which combines Synageva’s proprietary compounds and technology with to-BBB’s expertise in CNS delivery, provides Synageva with an opportunity to extend the therapeutic benefits of our pipeline products targeting rare diseases with CNS manifestations.”

“We are very pleased to collaborate with Synageva,” said Pieter Gaillard, CSO of to-BBB. “to-BBB’s brain delivery technology combined with Synageva’s significant rare disease expertise should result in substantial progress towards the development of innovative medicines for untreated CNS diseases.”

About Synageva BioPharma Corp.

Synageva BioPharma Corp. is dedicated to discovering, developing and commercializing therapies for patients with rare conditions and high-unmet medical need. The Company has developed a pipeline of novel therapeutics for under-served populations and has assembled a team with a proven record of bringing orphan therapies to patients. Further information regarding Synageva BioPharma Corp. is available at www.synageva.com.

About to-BBB

to-BBB is a private biotechnology company focusing on enhanced drug delivery across the blood-brain barrier. The Company is developing novel treatments for devastating brain disorders, such as brain cancer, neurodegenerative diseases and lysosomal storage diseases, by combining existing drugs with the G-Technology®, to-BBB’s proprietary brain delivery platform. This technology combines the well-established drug delivery approach of pegylated liposomes with the endogenous tripeptide glutathione as targeting ligand in a novel and safe way. Together with several top tier pharma and biotech companies, to-BBB is investigating the versatility of the G-Technology® for drugs that are unable to reach the brain within a tolerable therapeutic window. to-BBB is applying the G-Technology® for the delivery of doxorubicin for the treatment of brain cancer as its internal lead product 2B3-101. to-BBB is headquartered in The Netherlands at the Leiden Bio Science Park and established a fully owned subsidiary, to-BBB Taiwan Ltd., in Taipei, Taiwan.



CONTACT:

Synageva Contacts
Company Contact:
Synageva BioPharma Corp.
Chris Heberlig, 781-357-9900
[email protected]
or
Media Contact:
BioComm Network
Michele Parisi, 925-429-1850
[email protected]
or
To-BBB Contacts
to-BBB technologies BV
Willem van Weperen
Chief Executive Officer
Tel: +31 71 3322252
[email protected]
or
Pieter Gaillard, PhD
Chief Scientific Officer
Tel: +31 71 3322251
[email protected]

KEYWORDS:   United States  Europe  North America  Netherlands  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Genetics  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Frontage is Growing to Meet All Your Needs! Click Here to Learn About the Next Generation of Frontage.

Cara Care, a digital health startup focused on digestive diseases, raised $7 million to bring its mobile app to more patients in the U.S.

Investors looked past the headline success of Sci-B-Vac, zeroed in on the failure to achieve a secondary objective and sent VBI’s stock down 66%.